Early PhaseOpportunity Target mid-stage biotech and CROs focused on CNS injury therapies who may partner for translational research, clinical trial support, or co-development as ReNetX approaches Phase 2 with AXER-204.

Small Team Advantage Leverage the startup profile (2-10 employees) to propose agile collaborations, fast-turnaround pilots, and strategic advisory partnerships with larger pharma seeking nimble CNS renewal platforms.

ClinicalReachGap Position AXER-204 as a unique mechanism to promote axonal growth by blocking inhibitory receptors, appealing to institutions pursuing innovative CNS regeneration approaches for SCI, glaucoma, and TBI.

FundingReadiness Highlight recent funding (nearly $10M) and recognized leadership to engage grant programs, non-dilutive funding opportunities, and potential strategic investors seeking early-stage biotech assets.

StrategicEngagements Capitalize on advisory board additions and leadership awards to open doors for executive-level introductions, sponsor-led roundtables, and collaboration with academic centers and government relations channels.